

# Efficacy and Safety of Fully Resorbable Sinus Drug-eluting Stents in Patients With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps After Surgery: A Prospective, Randomized Controlled Trial

NCT07498374

---

Status	RECRUITING
Phase	Not Applicable
Sponsor	Tang-Du Hospital
Enrollment	192 participants

## Key Eligibility Criteria

---

### Inclusion (11)

- Part A
- Age 18-65 years.
- Diagnosis of chronic rhinosinusitis with nasal polyps (CRSwNP).
- Eosinophilic subtype confirmed by pathology (eosinophils  $\geq$ 27% of total infiltrating inflammatory cells in polyp tissue, OR absolute count  $\geq$ 55 eosinophils per high-power field (HPF) on H&E staining).
- Indicated and scheduled for Functional Endoscopic Sinus Surgery (FESS) due to inadequate response to standard medical therapy for  $\geq$ 3 months, with bilateral endoscopic Nasal Polyp Score (NPS)  $\geq$ 5 (max 8), each side  $\geq$ 2, and presenting at least 2 of the following symptoms before screening: nasal blockage/congestion, anterior/posterior nasal discharge, facial pain/pressure, or reduced/loss of smell.

... and 6 more (see full listing online)

### Exclusion (22)

- Previous nasal surgery within 6 months before screening that altered lateral wall structure and precludes polyp assessment.
- Allergy to corticosteroids or any component of the fully degradable sinus drug-eluting stent.
- Severe systemic disease contraindicating surgery.
- Other significant nasal diseases (e.g., sinonasal tumor, fungal sinusitis).
- Uncontrolled systemic diseases (e.g., severe cardiac, hepatic, renal dysfunction, diabetes).

... and 17 more (see full listing online)

## Locations (1 total)

---

Tangdu Hospital, Air Force Medical University, Xi'an, Shaanxi, China., Xi'an, Shaanxi, China